Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-11-2003 | Review

The impact of anti-angiogenic agents on cancer therapy

Author: Dieter Marmé

Published in: Journal of Cancer Research and Clinical Oncology | Issue 11/2003

Excerpt

Initiation, development and malignant progression of tumors depend on multiple genetic alterations as well as posttranscriptional and posttranslational modifications within the tumor cells. All these changes contribute to the loss of cell cycle control and to the evasion of programmed cell death. Along with the progression to the malignant phenotype, tumors develop a substantial cross-talk with the host tissue. This results in sustained angiogenesis and in tissue invasion, leading finally to metastasis. Thus, the diverse collection of genetic alterations leading to oncogenes with dominant gain of function and to tumor suppressor genes with recessive loss of function manifest four essential alterations in cell physiology that collectively dictate malignant growth: loss of cell cycle control, escape from apoptosis, sustained angiogenesis and metastasis. Hallmarks of these processes are distinct changes in cellular and inter-cellular signalling (Hanahan et al. 2000). As our knowledge of the various signalling pathways increases, those critical steps within these pathways that are altered in tumor cells or stromal cells are being unravelled. The cumulative knowledge of these changes within the different tumor types will help us to identify specific targets for the development of novel cancer therapies. …

Adams RH, Wilkinson GA, Weiss C, Diella F, Gale NW, Deutsch U, Risau W, Klein R (1999) Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. Genes Dev 13:295–306PubMed

Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogeneis in physiological and pathological neovascularization. Circ Res 85:221–228PubMed

Auerbach W, Auerbach R (1994) Angiogenesis inhibition: a review. Pharmacol Ther 63:265–311CrossRefPubMed

Bach TL, Barsigian C, Chalupowicz DG, Busler D, Yaen CH, Grant DS, Martinez J (1998) VE-cadherin mediates endothelial cell capillary tube formation in fibrin and collagen gels. Exp Cell Res 238:324–334CrossRefPubMed

Barleon B, Siemeister G, Martiny-Baron G, Weindel K, Herzog C, Marmé D (1997) Vascular endothelial growth factor up-regulates its receptor fms-like tyrosine kinase 1 (FLT-1) and a soluble variant of FLT-1 in human vascular endothelial cells. Cancer Res 57:5421–5425PubMed

Barleon B, Totzke F, Herzog C, Blanke S, Kremmer E, Siemeister G, Marme D, Martiny-Baron G (1997) Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 272:10382–10388PubMed

Basche M, Sandler AB, Eckhardt SG, Bunn PA, Holden SN, Pierson AS, Jenner W, Paty V, Persky M, Aitchison RD, Gordon GS, Parker VP, Usman N, Rothenberg ML (2002) Angiozyme, an anti-VEGFR1 ribozyme, carboplatin, and paclitaxel: results of a phase I study. Proc ASCO 21:445

Bauer JA, Morrison B, Oates R, Lee P, Borden E, Lindner DJ (2003) ANGIOZYME and interferon-α2b synergistically inhibit tumor angiogenesis. Proc AACR 44:1159

Bergsland E, Hurwitz H, Fehrenbacher L, Meropol N, Novotny W, Gaudreault J, Lieberman G, Kabbinavar F (2000) A randomized phase II trial comparing rhuMAb VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus 5-fluorouracil/leucovorin (FU/LV) to FU/LV alone in patients with metastatic colorectal cancer. Proc ASCO 19:939

Brantley DM, Cheng, N, Thompson, EJ, Lon, Q, Brekken RA, Thorpe PE, Muraoka RS, Cerretti DP, Pozzi A, Jackson D, Lin C, Chen J (2002) Soluble Eph A receptors inhibit tumor angiogenesis and progression in vivo. Oncogene 21:7011–7026CrossRefPubMed

Brooks PC, Stromblad S, Klemke R, Visscher D, Sarkar FH, Cheresh DA (1995) Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin. J Clin Invest 96:1815–1822PubMed

Brooks PC, Stromblad S, Sanders LC, von Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP, Cheresh DA (1996) Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3.Cell 85:683–693PubMed

Brooks PC, Silletti S., von Schalscha TL, Friedlander M, Cheresh DA (1998) Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity. Cell 92:391–400PubMed

Burke PA, DeNardo SJ, Miers LA, Lamborn KR, Matzku S, DeNardo GL (2001) Cilengitide targeting of alpha(v)beta(3) integrin receptor synergizes with radioimmunotherapy to increase efficacy and apoptosis in breast cancer xenografts. Cancer Res 62:4263–4272

Carlomagno F, Vitagliano D, Guida T, Ciardiello F, Tortora G, Vecchio G, Ryan AJ, Fontanini G, Fusco A, Santoro M (2002) ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently block oncogenic RET kinases. Cancer Res 62:7284–7290PubMed

Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257PubMed

Carmeliet P, Lampugnani M-G, Moons L, Breviario F, Compernolle V, Bono F, Balconi G, Spagnuolo R, Oosthuyse B, Dewerchin M, Zanetti A, Angellilo A, Mattot V, Nuyens D, Lutgens E, Clotman F, de Ruiter MC, Gittenberger-de Groot A, Poelmann R, Lupu F, Herbert J-M, Collen D, Dejana E (1999) Targeted deficiency or cytosolic truncation of the VE-cadherin gene in mice impairs VEGF-mediated endothelial survival and angiogenesis. Cell 98:147–157PubMed

Carnemolla B, Borsi L, Balza E, Castellani P, Meazza R, Berndt A, Ferrini S, Kosmehl H, Neri D, Zardi L (2002) Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood 99:1503–1504CrossRef

Chad May, Paul Balderes, Rashed Abdullah, Jacqueline Doody, Sherry Xu, Yan Wu, Zhenping Zhu, Paul Kussie, Elisabetta Dejana, Daniel Hicklin, Peter Bohlen, Fang Liao (2003) Characterization of the binding epitope of the anti-angiogenic non-toxic monoclonal antibody E4G10 against VE-cadherin. Proc AACR 44:2953

Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, Goodman SL, Kessler H (1999) N-methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem 42:3033–3040CrossRefPubMed

DeVore R, Fehrenbacher L, Herbst R, Langer C, Kelly K, Gaudreault J, Holmgren E, Novotny W, Kabbinavar F (2000) A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc ASCO 19:1896

Dias S, Hatori K, Zhu Z, Hicklin DJ, Witte L, Moore MAS, Rafii S (2001) Anti-angiogenesis therapy revisited: targeting both paracrine and autocrine angiogenic signaling pathways with neutralizing antibodies to VEGFR2 is essential to inhibit tumor growth. Proc AACR 42:3051

Drevs J, Mross K, Fuxius S, Müller M, Dugan M, Peng B, Chong J, Henry A, Laurent D, Pütz B, Marmé D, Unger C (2001) A phase-1 dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor inhibitor PTK787/ZK222584 (PTK/ZK) in patients with liver metastasis of advanced cancer. Proc ASCO 20:398

Drevs J, Schmidt-Gersbach CIM, Mross K, Dugan M, Lee L, Mietlowski W, Zirrgiebel U, George D, Yung A, Rich J, Steward WP, Thomas A, Laurent D, Unger C, Marmé D (2002) Biomarkers (VEGF, bFGF) for assessing the biological activity of PTK787/ZK222584 (PTK/ZK), a vascular endothelial growth factor (VEGF) receptor inhibitor, in tumors known to overexpress VEGF. Eur J Cancer 38:246

Eriksson U, Alitalo K (1999) Structure, expression and receptor-binding properties of novel vascular endothelial growth factors. Curr Top Microbiol Immunol 237:41–57PubMed

Eskens FA, Dumez H, Hoekstra R, Perschl A, Brindley C, Bottcher S, Wynendaele W, Drevs J, Verweij J, van Oosterom AT (2003) Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours. Eur J Cancer 39:917–926CrossRefPubMed

Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA (1995) Definition of two angiogenic pathways by distinct αν integrins. Science 270:1500–1502PubMed

Friedlander M, Theesfeld CL, Sugita M, Fruttiger M, Thomas MA, Chang S, Cheresh DA (1996) Involvement of integrins α_νβ3 and α_νβ5 in ocular neovascular diseases. Proc Natl Acad Sci USA 93:9764–9769CrossRefPubMed

George D, Jonasch E, Hart L, Lentz J, Parker K, Henry A, Pfister C, Dugan M, Laurent D, Clark J, Kaelin WG, Oh W, Kantoff P (2002) A phase I, dose-escalating and pharmacokinetic (PK) study of the VEGF-receptor inhibitor PTK787/ZK222584 (PTK/ZK) in patients with advanced renal cell or prostate carcinomas. Proc AACR 43:548

Gerety SS, Wang HU, Chen ZF, Anderson DJ (1999) Symmetrical mutant phenotypes of the receptor EphB4 and its specific transmembrane ligand ephrin-B2 in cardiovascular development. Mol Cell 4:403–414PubMed

Giancotti FG, Ruoslahti E (1999) Integrin signaling. Science 285:1028–1032CrossRefPubMed

Gordon MS, Talpaz M, Margolin K, Holmgren E, Sledge GWJ, Benjamin R, Stalter S, Shak S, Adelman D (1998) Phase I trial of recombinant humanized monoclonal anti-vascular endothelial growth factor (anti-VEGF mAb) in patients (PTS) with metastatic cancer. Proc ASCO 17:809

Halin C, Rondini S, Nilsson F, Berndt A, Kosmehl H, Zardi L, Neri D (2002) Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature. Nat Biotechnol 20:264–269CrossRefPubMed

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57–70PubMed

Hicklin DJ, Witte L, Zhu Z, Liao F, Wu Y, Li Y, Bohlen P (2001) Monoclonal antibody strategies to block angiogenesis. DDT 6:517–528CrossRefPubMed

Holash J, Davis S, Papadopoulos N, Croll SD, Ho L, Russell M, Boland P, Leidich R, Hylton D, Burova E, Ioffe E, Huang T, Radziejewski C, Bailey K, Fandl JP, Daly T, Wiegand SJ, Yancopoulos GD, Rudge JS (2002) VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA 99:11393–11398CrossRefPubMed

Holder N, Klein R (1999) Eph receptors and ephrins: effectors of morphogenesis. Development 126:2033–2044PubMed

Hood JD, Cheresh DA (2002) Role of integrins in cell invasion and migration. Nat Rev Cancer 2:91–100CrossRefPubMed

Hood JD, Bednarski M, Frausto R, Guccione S, Reisfeld RA, Xiang R, Cheresh DA (2002) Tumor regression by targeted gene delivery to the neovasculature. Science 296:2404–2407CrossRefPubMed

Huber J, Bassi R, Hooper A, Prewett M, Bohlen P, Hicklin DJ (2001) Anti-vascular endothelial factor receptor-2 monoclonal antibody DC101 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Proc AACR 42:4420

Hu-Lowe D, Hallin M, Feeley R, Zou H, Rewolinski D, Wickman G, Chen E, Kim Y, Riney S, Reed J, Heller D, Simmons B, Kania R, McTigue M, Niesman M, Gregory S, Shalinsky DR, Bender S (2002) Characterization of potency and activity of the VEGF/PDGF receptor tyrosine kinase inhibitor AG013736. Proc AACR 43:5356

Hurwitz H, Holden SN, Eckhardt SG, Rosenthal M, de Boer R, Rischin D, Green M, Basser R (2002) Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Proc ASCO 21:325

Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S (1998) Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58:1048–1051PubMed

Jani JP, Beebe JS, Emerson E, Gant T, Goodwin P, Higdon C, Hillerman S, Intrieri C, Knauth L, Marx M, Noe M, Rossi AM, Saga (2002) CP-547,632, a novel VEGFR-2 tyrosine kinase inhibitor for cancer therapy. Proc AACR 43:5359

Jones-Bolin S, Hunter K, Zhao H, Ruggeri B (2002) The effects of the orally acitve VEGF-R kinase inhibitor, CEP-7055, on primary tumor growth and metastatic profile in orthotopic models of human pancreatic ductal carcinoma and murine renal carcinoma (RENCA) in mice. Proc AACR 43:601

Jones-Bolin SE, Zhao H, Hunter K, Ruggeri B (2003) Effects of chronic orla administration of the pan VEGF-R kinse inhibitor, CEP-7055, alone and in combination wtih temozolomide (TMZ), on primary tumor growth, neurological dysfunction, and survival in an orthotopic model fo human glioblastoma in nude mice. Proc AACR 44:61

Kawai H, Li H, Chun P, Avraham S, Avraham HK (2002) Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells. Oncogene 21:7730–7739CrossRefPubMed

Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, Rudge JS, Holash J, Yancopoulos GD, Kandel JJ, Yamashiro DJ (2002) Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci 99:11399–11404CrossRefPubMed

Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS, Ferrara N (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844PubMed

Kullander K, Klein R (2002) Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol 3:475–486CrossRefPubMed

Laird AD, Vajkoczy P, Shawver LK, Thurnher A, Liang C, Mohammadi M, Schlessinger J, Ullrich A, Hubbard SR, Blake RA, Fong TA, Strawn LM, Sun L, Tang C, Hawtin R, Tang F, Shenoy N, Hirth KP, McMahon G, Cherrington (2000) SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 60:4152–4160PubMed

Liao F, Li Y, O'Connor W, Zanetta L, Bassi R, Santiago A, Overholser J, Hooper A, Mignatti P, Dejana E, Hicklin DJ, Bohlen P (2000) Monoclonal antibody to vascular endothelial-cadherin is a potent inhibitor of angiogenesis, tumor growth, and metastasis. Cancer Res 60:6805–6810PubMed

MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE (2001) Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery 48:151–157PubMed

Mäkinen T, Veikkola T, Mustjoki S, Karpanen T, Catimel B, Nice EC, Wise L, Mercer A, Kowalski H, Kerjaschki D, Stacker SA, Achen MG, Alitalo K (2001) Isolated lymphatic endothelial cells transduce growth survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J 20:4762–4773CrossRefPubMed

Marme D (1999) VEGF-mediated tumor angiogenesis: a new target for cancer therapy. In: Vaupel, Kelleher (eds) Tumor hypoxia: pathophysiology, clinical significance and therapeutic perspectives. Wiss Verlagsgesellschaft mbH, Stuttgart, pp 125–129

Matter A (2001) Tumor angiogenesis as a therapeutic target. Drug Disc Tech 6:1005–1024CrossRef

Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337PubMed

Mitjans F, Meyer T, Fittschen C, Goodman S, Jonczyk A, Marshall JF, Reyes G, Piulats J (2000) In vivo therapy of malignant melanoma by means of antagonists of alphav integrins. Int J Cancer 87:716–723

Navarro P, Caveda L, Breviario F, Mandoteanu I, Lampugnani MG, Dejana E (1995) Catenin-dependent and -independent functions of vascular endothelial cadherin. J Biol Chem 270:30965–30972CrossRefPubMed

O'Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KW, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101:3597–3605CrossRefPubMed

Papoutsi M, Siemeister G, Weindel K, Tomarev SI, Kurz H, Schächtele C, Martiny-Baron G, Christ B, Marmé D, Wilting J (2000) Active interaction of human A375 melanoma cells with the lymphatics in vivo. Histochem Cell Biol 114:373–385PubMed

Pavco PA, Bouhana KS, Gallegos AM, Agrawal A, Blanchard KS, Grimm SL, Jensen KL, Andrews LE, Wincott FE, Pitot PA, Tressler RJ, Cushman C, Reynolds MA, Parry TJ (2000) Antitumor and antimetastatic activity of ribozymes targeting the messenger RNA of vascular endothelial growth factor receptors. Clin Cancer Res 6:2094–2103PubMed

Posey JA, Ng TC, Yang B, Khazaeli MB, Carpenter MD, Fox F, Needle M, Waksal H, LoBuglio AF (2003) A phase I study of anti-kinase insert domain-containing receptor antibody, IMC-1C11, in patients with liver metastases from colorectal carcinoma. Clin Cancer Res 9:1323–1332PubMed

Rafii S (2000) Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest 105:17–19PubMed

Rafii S, Lyden D, Benezra R, Hattori K, Heissig B (2002) Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? Nature Rev Cancer 2:826–835CrossRef

Raymond E, Faivre S, Very K, Delbaldo C, Robert C, Brega N, Achour A, Massimini G, Schigalla P, Armand JP (2002) First results of a phase I and pharmacokinetic study of SU011248, a novel oral anti-angiognic agent, in patients with advanced solid tumours. Eur J Cancer 38 [Suppl 7]:17

Reyes M, Dudek A, Jahagirdar B, Koodie L, Marker PH, Verfaillie CM (2002) Origin of endothelial progenitors in human postnatal bone marrow. J Clin Invest 109:337–346CrossRefPubMed

Rosen LS, Rosen PJ, Kabbinavar F, Mulay M, Mickey J, Hernandez L, Brown JM, Alexancer J, Bello C, Cropp G, Kelsey S, Scigalla P (2001) Phase I exerience with SU6668, a novel multiple receptor tyrosine kinase inhibitor in patients with advanced malignancies. Proc ASCO 20:383

Ruggeri BA, Singh J, Hudkins R, Gingrich D, Angeles T, Robinson C, Chang H, Hunter K, Dobrzanski P, Pritchard S, Vaught J, Dionne C (2002) CEP-7055: an orally-active VEGF-R kinase inhibitor with potent anti-angiogenic activity and anti-tumor efficacy against human tumor xenograft growth. Proc AACR 43:5347

Salven P, Mustjoki S, Alitalo R, Alitalo K, Rafii S (2003) VEGFR-3 and CD133 identify a population of CD34+ lymphatic/vascular endothelial precursor cells. Blood 101:168–172CrossRefPubMed

Shaheen RM, Davis DW, Liu W, Zebrowski BK, Wilson MR, Bucana CD, McConkey DJ, McMahon G, Ellis LM (1999) Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res 59:5412–5416PubMed

Shaheen RM, Tseng WW, Davis DW, Liu W, Reinmuth N, Vellagas R, Wieczorek AA, Ogura Y, McConkey DJ, Drazan KE, Bucana CD, McMahon G, Ellis LM (2001) Tyrosine kinase inhibition of multiple angiogenic growth factor receptors improves survival in mice bearing colon cancer liver metastases by inhibition of endothelial cell survival mechanisms. Cancer Res 61:1464–1468PubMed

Siemeister G, Schirner M, Weindel K, Reusch P, Menrad A, Marmé D, Martiny-Baron G (1999) Two independent mechanisms essential for tumor angiogenesis: inhibition of human melanoma xenograft growth by interfering with either the vacular endothelial growth factor receptor pathway or the tie-2 pathway. Cancer Res 59:3185–3191PubMed

Sipkins DA, Cheresh DA, Kazemi MR, Nevin LM, Bednarski MD, Li KC (1998) Detection of tumor angiogenesis in vivo by alphaVbeta3-targeted magnetic resonance imaging. Nat Med 4:623–626PubMed

Sledge G, Miller K, Novotny W, Gaudreault J, Ash M, Cobleigh M (2000) A phase II trial of single-agent rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer. Proceedings ASCO 19:5C

Sweeney P, Karashima T, Kim SJ, Kedar D, Mian B, Huang S, Baker C, Fan Z, Hicklin DJ, Pettaway CA, Dinney CP (2002) Anti-vascular endothelial growth factor receptor 2 antibody reduces tumorigenicity and metastasis in orthotopic prostate cancer xenografts via induction of endothelial cell apoptosis and reduction of endothelial cell matrix metalloproteinase type 9 production. Clin Cancer Res 8:2714–2724PubMed

Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AIM, Master Z, Bendeck MP, Alitalo K, Dumont DJ, Yancopoulos GD, Stewart DJ (2001) Biological action of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie-2. Cardiovasc Res 49:659–670CrossRefPubMed

Thomas A, Morgan B, Drevs J, Jivan A, Buchert M, Horsfield M, Hennig, J, Mross, K, Henry A, Ball H, Peng B, Fuxius S, Unger C, O'Byrne KO, Laurent D, Dugan M, Steward W (2001) Pharmacodynamic results using dynamic contrast enhanced magnetic resonance imaging, of two phase 1 studies of the VEGF inhibitor PTK787/ZK 222584 in patients with liver metastases from colorectal cancer. Proc ASCO 20:#279

Tolcher AW, O'Leary JJ, DeBono JS, Caulkins JD, Molpus K, Sutula K, Ferrante KJ, Gualberto A, Noe DA, Huberman M, Rowinsky EK, Healey D (2002) A phase I and biologic correlative study of an oral vascular endothelial growth factor receptor-2 (VEGFR-2) tyrosine kinase inhibitor, CP-547,632, in patients (pts) with advanced solid tumors. Proc ASCO 21:334

Varner JA, Brooks PC, Cheresh DA (1995) Review: the integrin α_νβ3: angiogenesis and apoptosis. Cell Adhes Commun 3:367–374PubMed

Wang HU, Chen ZF, Anderson DJ (1998) Molecular distinction and angiogenic interaction between embryonic arteris and veins revealed by ephrin-B2 and its receptor Eph-B4. Cell 93:741–753PubMed

Ward BK, Heinrichs JH, Mancini M, Xu Y, Langermann S, Kiener P, Tice DA, Woessner R (2003) Inhibition of growth of human melanoma xenografts by Vitaxin, a humanized monoclonal antibody specific for α_νβ₃. Proc AACR 44:6430

Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Boffey SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA, Hughes GD, Thomas AP, Stokes ESE, Curry B, Richmond GHP, Wadsworth PF, Bigley AL, Hennequin LF (2002) ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 62:4645–4655PubMed

Weng DE, Weiss P, Kellackey C, Ganapathi R, Parker VP, Usman N, Cowens JW, Smith JA, Jackson TE, Radka SF, DiFrancesco A, Kim JA, Borden EC (2001) Angiozyme pharmacokinetic and safety results: a phase I/II study in patients with refractory solid tumors. Proc ASCO 20:393

Wickman G, Hallin M, Amundson K, Acena A, Grazzini M, Dillon R, M Herrmann, Vekich S, Bender S, Shalinsky DR, Hu-Lowe DD (2003) Further characterization of the potent VEGF/PDGF receptor tyrosine kinase inhibitor AG-013736 in preclinical tumor models for its antiangiogenesis and antitumor activity. Proc AACR 44:3780

Wilmes LJ, Hylton N, Wang DH, Fleming L, Gibbs J, Kim Y, Dillon R, Brasch RC, Park JW, Li K-L, Henry R, Partridge S, Shalinsky DR, Hu-Lowe D, McShane TM, Pallavicini MG (2003) AG-013736, a novel VEGFR TK inhibitor, suppresses tumor growth and vascular permeability in human BT474 breast cancer xenografts in nude mice. Proc AACR 44:3772

Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E, Rösel J, Schnell C, Stover D, Theuer A, Towbin H, Wenger F, Woods-Cook K, Menrad A, Siemeister G, Schirner M, Thierauch KH, Schneider MR, Drevs J, Martiny-Baron G, Totzke F, Marmé D (2000) PTK787/ZK 222584, a novel and potent inhibitor fo VEGF receptor tyrosine kinases, impairs VEGF-induced responses and tumor growth after oral administration. Cancer Res 60:2178–2189PubMed

Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J (2000) Vascular-specific growth factors and blood vessel formation. Nature 407:242–248PubMed

Yiong HQ, Herbst R, Faria S, Davis D, Scholz C, Jackson E, Madden T, McConkey D, Hicks M, Hess K, Charnsangavel C, Abbruzzese J (2003) A phase I surrogate endpoint trial of SU6668 in patients with solid tumors. Proc AACR 44:5345

Title: The impact of anti-angiogenic agents on cancer therapy
Author: Dieter Marmé
Publication date: 01-11-2003
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 11/2003
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-003-0488-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The impact of anti-angiogenic agents on cancer therapy

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2003

Up-regulation of cytoskeletal-associated protein 2 in primary human gastric adenocarcinomas

Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells

Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer

Characterisation of biomolecular profiles in primary high-grade prostate cancer treated by radical prostatectomy

Differential alterations of the genes in the CDKN2A-CCND1-CDK4-RB1 pathway are associated with the development of head and neck squamous cell carcinoma in Indian patients

Superiority of combined chemo-embolization and portal infusion with 5-fluorouracil over locoregional infusion concepts in Novikoff hepatoma-bearing rats

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page